Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EBITDA (2016 - 2025)

Mimedx's EBITDA history spans 15 years, with the latest figure at $21.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 90.66% year-over-year to $21.1 million; the TTM value through Dec 2025 reached $63.9 million, up 8.53%, while the annual FY2025 figure was $63.9 million, 8.53% up from the prior year.
  • EBITDA for Q4 2025 was $21.1 million at Mimedx, down from $22.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $23.4 million in Q2 2024 and bottomed at -$9.6 million in Q2 2022.
  • The 5-year median for EBITDA is $10.9 million (2023), against an average of $6.9 million.
  • The largest annual shift saw EBITDA crashed 2250.24% in 2022 before it surged 3981.76% in 2024.
  • A 5-year view of EBITDA shows it stood at $1.3 million in 2021, then soared by 780.23% to $11.3 million in 2022, then surged by 36.97% to $15.5 million in 2023, then dropped by 28.65% to $11.1 million in 2024, then surged by 90.66% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's EBITDA are $21.1 million (Q4 2025), $22.2 million (Q3 2025), and $12.4 million (Q2 2025).